News

Cancer vaccines
and HIV/AIDS vaccines
Publications

Read online or
download publications

go to library

News

  2014.04.23

New partner in Turkey

Hasbiotech is Recombio´s exclusive partner in Turkey. For more information on how to get access to Vaxira® in this territory please contact:

Bugraer Aslan

Mail: baslan@hasbiotech.com
Tel.: 0 216 339 81 49 (Ext:120)
Fax: 0 216 340 50 38

  2013.06.04

ASCO 2013

Racotumomab was safeand showed a promising survival improvement in advanced NSCLC patients in progression after first line onco-specific treatment (presented at ASCO 2013).

view more
  2012.09.28

ESMO 2012

A randomized, placebo controlled, double blind clinical trial with NSCLC patients shows increased in overall survival for racotumomab treatment (presented at ESMO 2012).

view more
  2011.03.03

Oncotic necrosis is induced by racotumomab treatment

Oncotic necrosis is induced by racotumomab treatment. Racotumomab immunotherapy of NSCLC patients induces anti-NeuGcGM3 antibodies , whose titer correlates with longer survival. The elicited antibodies kill tumor cells in vitro through a complement-independent mechanism. Rather, it involves cytoskeleton reorganization and the formation of wide cell membrane lesions and cellular swelling.

view more
  2010.09.01

NeuGc-GM3/VSSP treatment is safe and immunogenic

NeuGc-GM3/VSSP treatment is safe and immunogenic. Metastatic breast cancer patients were included in a phase II clinical trial in Camagüey, Holguín, Villa Clara and Santiago de Cuba. NeuGc-GM3/VSSP treatment was safe as compared to the best available clinical support and induced IgM and IgG antibodies capable of binding NeuGc-GM3 con cancer cells and of inhibiting NeuGc-GM3-mediated loss of function of T lymphocytes.

view more
  2010.03.17

Immunohistochemical studies performed at the J. P. Garrahan Pediatric Hospital, Buenos Aires, Argentina.

Reported studies for the first time the expression of N-glycolylated gangliosides in pediatric solid tumors. Around 88% of the specimens of Wilms tumor analysed were stained by the 14F7 monoclonal antibody, a mouse IgG1 that specifically recognizes NeuGc-GM3. Of note, no NeuGc-GM3 was detected in all samples of nontumoral kidney tissue analysed. The authors argue that the implementation of NeuGc-GM3-targeted immunotherapy alone or in combination with the current chemotherapeutic protocols might reduce the need for high-dose cytotoxic drugs or improve the outcome in chemotherapy-resistant patients.

  2009.09.12

Molecular modelling collaborative studies.

Molecular modelling collaborative studies performed at the Center of Molecular Immunology and the University of Oslo pinpointed the sequences of P3, an anti-ganglioside antibody, involved in the interaction with both its immunogen (ganglioside N-glycolyl GM3) and the anti-idiotypic antibody racotumomab. The binding sites to the latter ligands partially overlap. The authors speculate on the immunogenetic mechanisms that might explain racotumomab's capacity to induce a P3-like anti-ganglioside immune responses.

view more
  2008.10.27

Characterization of the antibody response against NeuGcGM3 ganglioside in non-small cell lung cancer.

view more